The FDA issued warning letters to approximately 30 telehealth companies on March 3, 2026, citing misleading direct-to-consumer marketing of compounded semaglutide and tirzepatide. Common findings included: (1) implied or explicit claims of FDA approval for compounded GLP-1 products; (2) claims of bioequivalence to Wegovy, Zepbound, Ozempic, or Mounjaro; and (3) failure to disclose the dispensing pharmacy or compounding pathway (503A vs 503B).
None of the named companies were on our 2026 ranking, but two were on adjacent watchlists. The action reinforces several pillars of our scoring rubric — specifically Pharmacy Traceability and Regulatory Clarity — and underscores why we down-weight providers that obscure their pharmacy partners or describe compounded GLP-1 medications as equivalent to FDA-approved drug products.
The agency's letters require corrective responses within 15 business days. Compounded GLP-1 medications remain legal where prepared by 503A licensed compounding pharmacies for individual patient prescriptions, or by 503B FDA-registered outsourcing facilities under cGMP-equivalent standards — but they are not FDA-approved drug products and are not the same as the brand-name versions.